Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide, Bortezomib and Abatacept for GvHD Prevention Following HSCT
NCT05289167Phase 2Recruiting
- Sponsor
- Northwell Health
- Start
- Mar 2022
- Primary completion
- Aug 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of abatacept in graft-versus-host disease (GVHD), sponsored by Northwell Health. Started Mar 2022; status: recruiting.
02
Drugs
abatacept
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT05289167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05289167.